PMC5397618_01
The graph shows the change of tumor size with course of treatment. The sum of the patient's tumor diameters increased after cessation of pazopanib therapy.
CRIOG2017-4801650.001.jpg
PMC5397618_01_CRIOG2017-4801650.001.jpg
fig1
Additionally, the sum of the patient's tumor diameters increased as follows: for lung metastases, by -10% (during the 3-month-pazopanib treatment) versus by 55% (during the two weeks after ceasing treatment); for liver metastases, by 0% versus by 33%; and for peritoneal dissemination, by 12% versus by 51% (Figure 1).
Transverse section of lung in computed tomography. (a) Start of pazopanib therapy. (b) End of pazopanib therapy. (c) After two weeks' cessation of pazopanib therapy.
CRIOG2017-4801650.002.jpg
PMC5397618_01_CRIOG2017-4801650.002.jpg
fig2
A CT scan taken three months after starting pazopanib treatment showed that the tumor sizes of the liver and lung metastases and of the peritoneal dissemination were stable (Figure 2). Particularly, the lung metastases sharply increased (Figure 2).